Payment overview · 2025
General Payments
$1,237.34
77 reported records · 16 companies
Healthcare provider profile · identity verified
Boyd P. Benefield, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · GULFPORT, MS · NPI 1356302574
Verified facts
What the public records show
CMS Open Payments records show Boyd P. Benefield, M.D. received $1,237.34 in general payments during 2025 across 77 reported records.
AstraZeneca Pharmaceuticals LP accounted for 20.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Ozempic by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $250.53 | 20.2% | 12 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $215.79 | 17.4% | 20 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $153.61 | 12.4% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $146.44 | 11.8% | 10 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $111.12 | 9.0% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $90.27 | 7.3% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $40.50 | 3.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $39.00 | 3.1% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $35.89 | 2.9% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $35.27 | 2.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.13 | 2.8% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.56 | 1.5% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $17.90 | 1.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.07 | 1.4% | 1 | 2025 |
| Ultragenyx Pharmaceutical Inc. | Unresolved — no canonical attribution shown | $15.69 | 1.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.57 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,237.34 | 77 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $160.51 | 15 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $158.93 | 6 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $153.61 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $148.29 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $134.36 | 8 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $111.12 | 7 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $90.27 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $86.65 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $71.16 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $67.48 | 6 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $55.28 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $40.50 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $39.00 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $39.00 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $34.13 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $18.56 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| Dojolvi Normalized: dojolvi |
Drug | Ultragenyx Pharmaceutical Inc. | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $12.08 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 38 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 135 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 79 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
79 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
135 | 28 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
38 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 708 | 154 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 656 | 148 |
| Levothyroxine Sodium | Levothyroxine Sodium | 478 | 96 |
| Atorvastatin Calcium | Atorvastatin Calcium | 423 | 108 |
| Lisinopril | Lisinopril | 396 | 85 |
| Gabapentin | Gabapentin | 371 | 84 |
| Trazodone Hcl | Trazodone Hcl | 328 | 56 |
| Metformin Hcl | Metformin Hcl | 322 | 79 |
| Escitalopram Oxalate | Escitalopram Oxalate | 321 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 314 | 75 |
| Omeprazole | Omeprazole | 302 | 70 |
| Diclofenac Sodium | Diclofenac Sodium | 294 | 91 |
| Losartan Potassium | Losartan Potassium | 264 | 70 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 254 | 41 |
| Potassium Chloride | Potassium Chloride | 248 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 220 | 63 |
| Famotidine | Famotidine | 218 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 200 | 46 |
| Meloxicam | Meloxicam | 195 | 46 |
| Alprazolam | Alprazolam | 190 | 34 |
| Ezetimibe | Ezetimibe | 189 | 43 |
| Quetiapine Fumarate | Quetiapine Fumarate | 183 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 182 | 43 |
| Donepezil Hcl | Donepezil Hcl | 174 | 35 |
| Simvastatin | Simvastatin | 168 | 43 |
| Zolpidem Tartrate | Zolpidem Tartrate | 160 | 26 |
| Primidone | Primidone | 150 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 142 | 21 |
| Celecoxib | Celecoxib | 139 | 33 |
| Ozempic | Semaglutide | 135 | 28 |
| Pregabalin | Pregabalin | 134 | 17 |
| Tramadol Hcl | Tramadol Hcl | 130 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 125 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 123 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 122 | 25 |
| Propranolol Hcl Er | Propranolol Hcl | 120 | 21 |
| Montelukast Sodium | Montelukast Sodium | 116 | 29 |
| Furosemide | Furosemide | 113 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 108 | 36 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 107 | 80 |
| Carvedilol | Carvedilol | 104 | 28 |
| Estradiol | Estradiol | 104 | 19 |
| Azithromycin | Azithromycin | 102 | 84 |
| Aripiprazole | Aripiprazole | 101 | 16 |
| Eliquis | Apixaban | 98 | 18 |
| Mirtazapine | Mirtazapine | 97 | 19 |
| Bupropion Xl | Bupropion Hcl | 90 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 87 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 86 | 11 |
| Clonidine Hcl | Clonidine Hcl | 81 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 79 | 17 |
| Atenolol | Atenolol | 70 | 15 |
| Nateglinide | Nateglinide | 70 | 19 |
| Fluconazole | Fluconazole | 69 | 43 |
| Buspirone Hcl | Buspirone Hcl | 68 | 15 |
| Raloxifene Hcl | Raloxifene Hcl | 68 | 14 |
| Levofloxacin | Levofloxacin | 66 | 49 |
| Meclizine Hcl | Meclizine Hcl | 65 | 26 |
| Sertraline Hcl | Sertraline Hcl | 62 | 16 |
| Glipizide | Glipizide | 61 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 60 | 13 |
| Allopurinol | Allopurinol | 59 | 14 |
| Lorazepam | Lorazepam | 59 | 13 |
| Methylprednisolone | Methylprednisolone | 59 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 58 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 57 | 42 |
| Spironolactone | Spironolactone | 55 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | 13 |
| Terbinafine Hcl | Terbinafine Hcl | 54 | 20 |
| Topiramate | Topiramate | 54 | suppressed |
| Naproxen | Naproxen | 53 | 15 |
| Terazosin Hcl | Terazosin Hcl | 53 | suppressed |
| Ondansetron Odt | Ondansetron | 52 | 29 |
| Prednisone | Prednisone | 52 | 14 |
| Ibuprofen | Ibuprofen | 51 | 19 |
| Nifedipine Er | Nifedipine | 49 | 13 |
| Risperidone | Risperidone | 49 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 49 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 49 | suppressed |
| Myrbetriq | Mirabegron | 48 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 45 | 12 |
| Synthroid | Levothyroxine Sodium | 45 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 45 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 16 |
| Mounjaro | Tirzepatide | 42 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 41 | suppressed |
| Bumetanide | Bumetanide | 40 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 40 | suppressed |
| Xarelto | Rivaroxaban | 40 | 11 |
| Azelastine Hcl | Azelastine Hcl | 39 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 38 | 11 |
| Gemtesa | Vibegron | 38 | 11 |
| Glimepiride | Glimepiride | 38 | 12 |
| Temazepam | Temazepam | 38 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 37 | 12 |
| Lansoprazole | Lansoprazole | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 11 |
| Valacyclovir | Valacyclovir Hcl | 37 | 13 |
| Farxiga | Dapagliflozin Propanediol | 36 | suppressed |
| Levetiracetam | Levetiracetam | 36 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 35 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Ramipril | Ramipril | 31 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 31 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 30 | suppressed |
| Finasteride | Finasteride | 29 | 11 |
| Jardiance | Empagliflozin | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Progesterone | Progesterone, Micronized | 26 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 25 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 24 | 23 |
| Valsartan | Valsartan | 24 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Colchicine | Colchicine | 22 | suppressed |
| Eszopiclone | Eszopiclone | 22 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 21 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 19 | 11 |
| Movantik | Naloxegol Oxalate | 19 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Praluent Pen | Alirocumab | 19 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Invokana | Canagliflozin | 17 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 17 | 16 |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Minoxidil | Minoxidil | 17 | suppressed |
| Pentoxifylline | Pentoxifylline | 17 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | 13 |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 15 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Verapamil Sr | Verapamil Hcl | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Thioridazine Hcl | Thioridazine Hcl | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Linezolid | Linezolid | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,237.34 · 77 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, Cologuard Collection Kit, Dojolvi, EVENITY, FARXIGA, FREESTYLE LIBRE, GEMTESA, Kerendia, MOUNJARO, NEXLETOL, Ozempic, QULIPTA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, Wegovy, YUPELRI, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error